The Latest Breaking News from Illumina

Illumina Reports 41% Dip In Q1 Profits Despite 12% Jump in Sales, Reaffirms FY22 Guidance

Illumina Inc's (NASDAQ:ILMN) Q1 FY22 revenues rose 12% Y/Y to $1.22 billion, in line with estimates. Nearly all revenues came from the core Illumina business; GRAIL, Illumina's cancer liquid biopsy subsidiary, recorded revenues of $10 million. Product revenue for the quarter totaled $1.07 billion, up 12%, and Service and other revenue amounted to…

Benzinga · May 6, 2022

Lessons For Elon Musk: 5 Notorious Failed Hostile Takeovers

As any student of industry knows, Elon Musk is hardly the first person to attempt a hostile takeover.

Benzinga · Apr 15, 2022

Here's How Much You Would Have Made Owning Illumina Stock In The Last 5 Years

Illumina (NASDAQ:ILMN) has outperformed the market over the past 5 years by 1.75% on an annualized basis producing an average annual return of 15.45%. Currently, Illumina has a market capitalization of $56.36 billion.

Benzinga · Apr 6, 2022

Expert Ratings For Illumina

Over the past 3 months, 5 analysts have published their opinion on Illumina (NASDAQ:ILMN) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's business to predict how a stock will trade over the upcoming year.

Benzinga · Feb 11, 2022

10 Biggest Price Target Changes For Friday

SVB Leerink cut Illumina, Inc. (NASDAQ: ILMN) price target from $430 to $400. Illumina shares fell 0.7% to $355.70 in pre-market trading.

Benzinga · Feb 11, 2022

Illumina's Q4 Profit Falls Despite Topline Growth Of 26%

Illumina Inc (NASDAQ: ILMN) reported 

Benzinga · Feb 11, 2022

Illumina: Q4 Earnings Insights

Illumina (NASDAQ:ILMN) reported its Q4 earnings results on Thursday, February 10, 2022 at 04:00 PM. Here's what investors need to know about the announcement. Earnings Illumina beat estimated earnings by 53.06%, reporting an EPS of $0.75 versus an estimate of $0.49.

Benzinga · Feb 10, 2022